Phase-II study of BBR 2778, a new aza-anthracenedione, in patients with relapsed aggressive non-Hodgkin lymphomas.

被引：0
|
作者：
Borchmann, P
Morschhauser, F
Schnell, R
Harousseau, JL
Gisselbrecht, C
Rudolph, C
Wilhelm, M
Derigs, H
Kutz, K
Leynardier, D
Verdi, E
Camboni, G
Engert, A
机构：
[1] Univ Cologne, Innere Med Klin, Cologne, Germany
[2] Jop Huriez, Lille, France
[3] CHU Hotel Dieu, Serv Hematol, Nantes, France
[4] Hop St Louis, Serv Hematol, Paris, France
[5] Carl Diehm Klinikum Cottbus, Innere Med Klin, Cottbus, Germany
[6] Universitatsklin, Innere Med Klin, Wurzburg, Germany
[7] Hesper Ltd, Allschwil, Switzerland
[8] Novuspharma Spa, Monza, Italy
[9] Univ Mainz, Innere Med Klin, D-6500 Mainz, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1441
引用
收藏
页码：341A / 341A
页数：1
相关论文
共 50 条
  • [21] Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma
    Borchmann, Peter
    Herbrecht, Raoul
    Wilhelm, Martin
    Morschhauser, Franck
    Hess, Georg
    Cernohous, Paul
    Veals, Susan A.
    Singer, Jack W.
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (04) : 620 - 628
  • [22] Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL).
    Goy, A
    Younes, A
    McLaughlin, P
    Pro, B
    Romaguera, J
    Hagemeister, F
    Fayad, L
    Trehu, EG
    Schenkein, D
    Rodriguez, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 577S - 577S
  • [23] A Phase 2 Study of Epothilone B Analog BMS-247550 (NSC 710428) in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas
    Churpek, Jane E.
    Pro, Barbara
    van Besien, Koen
    Kline, Justin
    Conner, Kathy
    Wade, James L., III
    Hagemeister, Fredrick
    Karrison, Theodore
    Smith, Sonali M.
    CANCER, 2013, 119 (09) : 1683 - 1689
  • [24] FLUDARABINE IN RELAPSED LOW-GRADE NON-HODGKIN LYMPHOMAS - A PHASE-II STUDY OF THE GERMAN LOW-GRADE LYMPHOMA STUDY-GROUP
    POTT, C
    UNTERHALT, M
    SANDFORD, D
    MARKERT, H
    FREUND, M
    ENGERT, A
    GASSMANN, W
    HOLTKAMP, W
    SEUFERT, M
    HELLRIEGEL, K
    KNAUF, B
    NIEBERDING, R
    EMMERICH, B
    KOCH, P
    WORMANN, B
    HIDDEMANN, W
    BLOOD, 1993, 82 (10) : A575 - A575
  • [25] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
  • [26] A phase-II trial of infusional etoposide, vincristine and doxorubicin with bolus cyclophosphamide (EPOCH) along with filgrastim support in patients with relapsed Hodgkin's and non-Hodgkin's lymphomas
    Jain, VK
    Ogden, J
    Mennel, R
    McIntyre, K
    Duncan, L
    Hyman, W
    BLOOD, 1997, 90 (10) : 850 - 850
  • [27] Phase II study of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymhoma (NHL)
    Younes, A
    McLaughlin, P
    Pro, B
    Hagemeister, F
    Bleyer, A
    BLOOD, 2003, 102 (11) : 639A - 640A
  • [28] Analysis of prognostic factors in patients with HIV-associated aggressive B-cell non-Hodgkin lymphomas.
    Mathew, Blessy Maria
    Dalia, Samir
    Hall, Joseph
    Kuykendall, Andrew
    Shah, Bijal D.
    Bello, Celeste M.
    Chervenick, Paul A.
    Sokol, Lubomir
    Sotomayor, Eduardo M.
    Chavez, Julio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin's and aggressive non-Hodgkin's lymphoma -: Results of a multicenter phase-II study.
    Josting, A
    Rudolph, C
    Mapara, M
    Ko, Y
    Söhngen, D
    Dorken, B
    Diehl, V
    Engert, A
    BLOOD, 2001, 98 (11) : 681A - 681A
  • [30] A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma
    Engert, A
    Schnell, R
    Kupper, F
    Reiser, M
    Engelhard, M
    Wilhelm, M
    Lathan, B
    BaltesEngler, S
    Winterhalter, B
    Scheulen, ME
    Dederichs, B
    Tesch, H
    Wormann, B
    Diehl, V
    LEUKEMIA & LYMPHOMA, 1997, 24 (5-6) : 513 - 522
12345